



CONSTANCE Y FEARS, JD, PHD

CEO & Principal Consultant
2300 Bethelview Road, Suite 110-189, Cumming, GA 30040
P: (470) 423-0185
constancefears@polymathregconsultants.com
www.polymathregconsultants.com

SKILL SET

Regulations & Standards: 21 CFR 210, 211, 600s, 800s, and Part 11, FD & C Act, ICH, EudraLex Parts I and II and Annexes (e.g., Annex 1), PIC/S, ISO (e.g., ISO-9001, ISO-13485), Good Distribution Practices (GDP), Good Documentation Practices, Data Integrity Principles, worldwide GMPs

Quality Assurance: GMP Audits, Inspection Readiness Activities for general inspections, pre-approval inspections (PAI), and pre-license inspections (PLI), Sterile Manufacturing/Sterility Assurance, GMP and Auditor Training, Quality Management Systems (QMS), GMP Compliance, Gap Assessments, Risk Evaluation, Health Authority Responses, Corrective and Preventive Actions (CAPA) effectiveness checks, Quality Metrics Assessment, Artificial Intelligence

Quality Control: Data Collection, Analysis, and Review, Microbiological Testing, UV/Vis, Chromatography, Spectrometry, Molecular Biology Assays and Techniques (e.g., various types of PCR, gene cloning in various vectors, ELISA, cell functional assays, gel electrophoresis, Western blotting, Bradford Assay, Flow Cytometry, Cell Culture, FISH.

Product Types: Finished Drugs, Active Pharmaceutical Ingredients (API), Drug Substances, Biologics (e.g., Vaccines, Gene Therapy), Medical Devices, Combination Products, Raw Materials, Cosmetics & Cosmetic Ingredients, Packaging and Labeling, Distribution

Applications: Microsoft® Office, Laboratory Information Management System (LIMS), eQMS, MyLearning, SharePoint, SAP, TrackWise, EDMS (e.g., Veeva), Atlas-Compliance, Redica, Blue Mountain, online learning platforms

Certifications/Special Training: Former US FDA Certified Level I Drug Investigator, Microbiology inspector for US FDA, US and EU laws and regulations

PROFESSIONAL EXPERIENCE

CEO & Principal Consultant

Polymath Regulatory Consultants, LLC

Jun. 2023 – present

Cumming, GA

- Provide expert knowledge of CGMPs, legislation, standards, and guidance documents to drug, cosmetic, and Medtech companies

- Research complex quality and CGMP compliance questions using artificial intelligence, legislation, regulations, industry benchmarking, peer-reviewed publications, etc.
- Perform inspection readiness activities for single or complex/multi-Agency CGMP inspections; inspection support/management; drafting responses to Agency inspection reports; warning letter remediation
- Conduct site CGMP/ISO audits and mock FDA inspections
- Author documents and conduct CGMP compliance review of Quality Management System (QMS)
- Develop and present CGMP training, including annual CGMP training
- Provide CGMP subject matter expertise for artificial intelligence and machine learning platforms

Adjunct Assistant Professor of Biotechnology

Morehouse School of Medicine, Masters in Biotechnology

Summer 2024 - present

Atlanta, GA

Relevant Courses Taught: Making Medical Devices

Director, Global CGMP Quality Compliance

Merck & Co., Inc.

June 2022 –June 2023

Remote

- Provided regulatory and inspectional intelligence using electronic platforms, e.g., Redica
- Served as a global subject matter expert for CGMPs for drug products, active pharmaceutical ingredients, vaccines, and medical devices
- Ensured new and developing global QMS standards and procedures impacting Merck manufacturing sites were fully compliant with international regulatory expectations
- Trended and analyzed inspectional observations received across the network for impact to various above-site teams and impact to the network as a whole
- Trended and analyzed inspectional observations and enforcement actions for impact and learning opportunities within the network
- Developed and oversaw a program to share significant site-level inspectional observations between sites and above-site teams to prevent recurrence
- Supported pre-approval inspection readiness and post-inspection remediation activities
- Supported global audit program by identifying audit targets and developing protocols for targeted assessments
- Participated in industry organizations and pharmaceutical benchmarking groups
- Assessed draft and finalized regulations/laws for an impact on global quality and compliance

Director, Global Quality Systems & Compliance

Merck & Co., Inc.

Jan. 2021 – Jun. 2022

Remote

- Served as global business owner of Quality Management System (QMS), responsible for compliance with and implementation of CGMP/GDP regulations for Annual Product Reviews, Recalls/Market Actions, Product Discontinuation, Product Quality Complaints, Management of Returned Goods, and Health Authority Reporting, e.g., FARs, BPDRs
- Monitored QMS health and proactively identified, investigated, and resolved trends and patterns before compliance and supply impact; defined and drove implementation of performance metrics, as appropriate, to measure effectiveness of the quality organization and management responsibilities activities across the network
- Authored and revised global QMS documents, e.g., quality standards and global procedures, for alignment with global regulatory requirements

- Monitored Health Authority regulations, issues, trends, and changes to ensure relevant regulations were incorporated into QMS documents
- Reviewed pending and new global regulations for impact on QMS topics and amended documents as needed
- Provided subject matter expertise (SME) in CGMPs for worldwide and supported audits and inspections
- Interfaced with Information Technology (IT) group to develop and implement IT tools to increase efficiency and CGMP compliance
- Initiated and led communities of practice (CoPs) or centers of excellence (CoEs) to drive best practice sharing and continuous improvements across the network
- Influenced and advocated positions on continued product assessment and reporting related to Health Authority expectations through a strong partnership with internal connections
- Anticipated external trends through benchmarking and regulatory intelligence activities and prepared the company proactively for changes and continuous improvements
- Led the development and execution of significant innovation projects driving operational improvement
- Acted as a member of the QMS Leadership Team
- Supervised and managed the QMS Team
- Drove continuous improvement initiatives within the QMS

Other Duties

- Divisional Quality Council (DQC) Coordinator- organized cross-departmental monthly meetings with senior management, including determination of topics to be covered, presenting Global Quality KPIs, managing action items, and drafting meeting minutes.

Director, Global Quality Compliance (Inspection Readiness)

Sept. 2018 – Jan 2021

Merck & Co., Inc.

Remote

- Monitored and reviewed new CGMP legislation, regulations, and guidance documents and reported to internal and external sites via quality councils and external communications
- Directly interacted with Health Authorities, e.g., during inspections by answering inquiries and acting as the liaison between the site and global level
- Served as global SME for CGMPs related to active pharmaceutical ingredients (APIs) and finished drugs for contract manufacturing organizations (CMOs)
- Reviewed global QMS documents to ensure compliance with regulatory requirements
- Assessed regulatory intelligence and partnered with External Quality Assurance (EQA) and CMO management to prepare for Health Authority inspections, e.g., mock inspections, inspection readiness, training, etc.
- Assessed regulatory trends and reported to internal and external sites via quality councils and external communications
- Provided on-site guidance during CMO Health Authority regulatory inspections
- Partnered with EQA and CMO management to identify appropriate corrective action and preventive action (CAPA) Plans to address global audit and Health Authority inspection observations
- Monitored CAPA status and ensured timely CAPA implementation and effectiveness
- Monitored and analyzed outcomes of Health Authority inspections to identify, investigate, and resolve trends and reported results to Quality Councils

- Reviewed and approved quality agreements

Special Projects:

- Lead for site implementation of Merck Global Nitrosamine Impurity Project (2020)
- Compliance review of global QMS documents for Material Management, ensuring compliance with regulations (2020)
- Compliance lead for supplier management of subcontractors (2020)
- Assisted with development of global inspection portal for remote inspections (2020)

Associate Director, Quality Assurance (Auditing & Compliance)

Oct. 2017 – Sept. 2018

Merck & Co., Inc.

Wilson, NC

- Site Lead Auditor & Compliance Lead:
 - Led all site internal audits, including drafting and issuing audit agendas and final audit reports
 - Led all CGMP-related regulatory inspections, including preparation, execution, response writing, CAPA tracking, and closeout
 - Managed auditing personnel
 - Mentored and supported new and existing site auditors to ensure performance of auditors contributed to the effectiveness of the internal audit program
 - Led change and process improvement initiatives related to auditing, inspections, CAPA, etc.
 - Presented site auditing metrics and emerging regulatory trends at site quality council
 - Reviewed and ensured audit and inspection responses and CAPAs were robust and performed CAPA effectiveness checks
 - Led continuous improvement projects related to auditing and inspection readiness
 - Led permanent inspection readiness activities– organizing SMEs, formulating the tour routes, and facilitating audit/inspection logistics
 - Drafted and reviewed Health Authority responses
 - Provided compliance advice to site related to development and commercial product teams

Special Projects:

- Developed and implemented site-wide Data Integrity Improvement Plan
- Developed and implemented an integrated approach to site auditing by combining permanent inspection readiness with the internal audit program.
- Developed global audit curriculum for use Merck-wide for the training of site internal auditors

Consumer Safety Officer

Nov. 2014 – Sept. 2017

U.S. Food and Drug Administration

Silver Spring, MD

Office of Regulatory Affairs (ORA)

Center for Drug Evaluation and Research (CDER)

- Performed independent CGMP inspections of pharmaceutical manufacturers worldwide
- Acted as inspectional SME for development of artificial intelligence and machine learning platform
- Assessed public comments on FDA draft guidance documents and provided legal and technical advisory opinions to senior management
- Performed data analytics on post-marketing events, e.g., FARs, complaints, and reported trends to senior management

- Served on working committees to improve Agency relationships with industry
- Authored inspectional dossiers for foreign and domestic drug inspections, advising inspectors of high-risk coverage topics and areas
- Drafted technical guidance documents, e.g., SOPs and work aids for Agency stakeholders
- Authored comprehensive establishment inspection reports (EIRs) using the FD&C Act, Compliance Programs and Guidance Manuals, and 21 CFR 210, 211, and ICH Q7
- Authored post-inspectional memoranda to drug firms addressing the adequacy of proposed CAPAs
- Collaborated directly with the Office of Compliance to obtain regulatory actions against non-compliant firms
- Partnered with state agencies (e.g., Georgia Department of Agriculture) and other Federal Agencies (e.g., Veterans Affairs)

Awards:

- 56th Annual FDA Awards Ceremony, August 8, 2016. Recognition for contributions to:
 - *Wallcur Simulated Saline Incident Task Force*- For sustained efforts in both containing the public health threat associated with simulated 0.9% sodium chloride bags and efforts to prevent future patient exposures.
 - *Drug Shortages Mobile Application Development Team*- For developing an innovative tool that will offer easier and faster access to important drug shortage information.
- Performance-based time and monetary awards and positive reviews from senior investigators, trainers, and trainees

Assistant Professor of Biology (Tenure Track)
Middle Georgia State University

August 2012 – Dec. 2014
 Cochran, GA

Relevant Courses Taught

Cell Biology, Molecular Biology, General Biology I and II, and Ethics in Bioscience

EDUCATION

University of Texas at Austin, School of Law
 Juris Doctorate (JD)

Austin, TX (USA)

Université Jean Moulin III, School of Law
 Diploma in International and French Law

Lyon (FRANCE)

University of Alabama at Birmingham, School of Medicine
 Doctor of Philosophy (PhD), Cell & Molecular Biology/Cancer Biology

Birmingham, AL (USA)

Florida State University
 Bachelor of Science in Biological Sciences

Tallahassee, FL (USA)

MEMBERSHIPS and ADVISORIES

- American Society for Quality (ASQ), Member and Speaker (presented “Audit Like An Inspector” in 2025)
- Parenteral Drug Association (PDA), Member and Speaker (see [Constance Fears JD, PhD | PDA](#)), a part of PDA 2025 Conference, panelist for “FDA Inspection Readiness”)
- Women in Manufacturing, Member
- Alpharetta Chamber of Commerce, Member
- Atlas Compliance, Regulatory Advisor
- Pathway for Patient Health, Guest Professor

PUBLICATIONS

Fears, C.Y., Woods, A. (2006) The Role of Syndecans in Disease and Wound Healing. *Matrix Bio.*, (25)7: 443-456.

Fears, C.Y. et al. (2006) Syndecan-2 is Expressed in the Microvasculature of Gliomas and Regulates Angiogenesis in Microvascular Endothelial Cells. *J. Bio. Chem.*, 281(21): 14533-36.

Fears, C.Y. et al. (2005) Low Density Lipoprotein Receptor-Related Protein Contributes to the Anti-Angiogenic Activity of Thrombospondin-2 in a Murine Glioma Model. *Can. Res.* 65(20): 9338-46.

Rege, T.A., Fears C.Y., Gladson C.L. (2005) Endogenous Inhibitors of Angiogenesis in Malignant Gliomas: Nature’s Anti-Angiogenic Therapy. *J. Neuro-oncology*, 7(2): 106-21.

Fears, C.Y. et al. (2004) Could Labeled Neuronal Progenitor Cells Be Used to Target Glioma Tumor Endothelium? *Can. Bio. & Ther.* 3(9): e118-119.

Repovic, P., Fears, C.Y., Gladson, C.L., Benveniste, E.N. (2003) Oncostatin-M Induction of Vascular Endothelial Growth Factor Expression in Astrogloma Cells. *Oncogene*, 22: 8117-8124.